Clinical Trial Update: Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women [Phase 2]

View source ↗

Summary

Phase 2 safety, reactogenicity and immunogenicity study of different formulations of GSK's investigational RSV vaccine (GSK3003891A) in healthy women has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GSK RSV vaccine (GSK3003891A) (RSV vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED | Results posted: 2017-08-16